SCDM Updated CCDM Exam Questions and Answers by ignacy

InElectronic Data Capture (EDC)system validation,User Acceptance Testing (UAT)is a mandatory phase that must becompleted before data collection begins in the production environment.

According to theGCDMP (Chapter: Database Design, Validation, and Testing)andFDA 21 CFR Part 11, UAT ensures that the EDC system meets allprotocol-specific, functional, and regulatory requirementsbefore it is deployed for live use. The goal is to verify that the system performs exactly as intended by simulating real-world user interactions withtest datain avalidated test environment.

Data collection prior to UAT completion would violate validation requirements and risk noncompliance withICH E6 (R2) GCP Section 5.5.3, which mandates that all computerized systems be validated and tested before use.

While options A and C describe correct components of testing strategy,the key regulatory requirementis thatUAT must be completed and approved before live data entry begins. Option D is incorrect — risk-based UAT is an accepted modern validation approach under bothFDA and GAMP5principles.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Validation, Section 5.3 – User Acceptance Testing

FDA 21 CFR Part 11 – Validation of Electronic Systems (Section 11.10(a))

ICH E6 (R2) GCP, Section 5.5.3 – Validation Before Use in Production Environment

When importing external data (e.g., laboratory or imaging results) into a clinical database, thefirst stepin data import quality control is to verify thatincoming files conform to the pre-specified data transfer specifications (DTS).

According to theGCDMP (Chapter: External Data Transfers and Integration), theData Transfer Specificationdefines file structure, variable names, data types, delimiters, record counts, and validation rules. The initial import check confirms that the received file matches the technical and structural requirements before content or record consistency is evaluated.

Subsequent checks—such as record counts (A), data consistency with existing database (C), and internal logical consistency (D)—are performed only after the file structure is validated and confirmed to match the specifications. Failure to perform this first check may cause import errors or corrupted data loads.

Thus, thefirst and most critical verification stepis ensuringfile conformity to the agreed data transfer specifications, makingoption Bcorrect.

Reference (CCDM-Verified Sources):

SCDM GCDMP, Chapter: External Data Transfers, Section 4.2 – Data Transfer File Validation and Import Checks

ICH E6(R2) GCP, Section 5.5.3 – Validation of Computerized Systems and Data Imports

For a well-maintained 100-subject study withongoing data cleaningandcompleted reconciliations, thedatabase lockprocess typically takesa few daysafter theLast Patient Last Visit (LPLV).

According to theGCDMP (Chapter: Database Lock and Archiving), the duration of the lock process depends on the level of data cleanliness at LPLV. If the study team has conducted continuous data cleaning, query resolution, and external data reconciliation throughout the trial, then the final lock steps (e.g., final data review, documentation, and approvals) can be completed in2–5 days.

However, if significant cleaning or reconciliation remains outstanding, lock may take several weeks. Since the question states that data are “maintained almost all clean,”Option B – a few days– is the appropriate estimate.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section 6.2 – Database Lock Preparation and Timelines

ICH E6 (R2) Good Clinical Practice, Section 5.5.3 – Data Quality and Lock Procedures

FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations – Data Lock and Archiving Procedures

When theprimary efficacy endpointin a clinical trial is3-month survival, the key data element required is thedeath date. This is because the survival endpoint is determined by calculating whether the subject lived or died within a defined time frame from study enrollment or randomization.

According to theGCDMP (Chapter: Data Management Planning and Study Start-up), the Clinical Data Manager (CDM) must identify and ensure the capture of allcritical data elementsnecessary to evaluate the study endpoints. For time-to-event analyses (e.g., survival studies), accurateevent dates (death date)are essential for endpoint derivation and statistical analysis.

Other data elements such as cause of death or date of autopsy (options B and C) may support secondary analyses or safety reviews but are not necessary to determine the survival endpoint itself. Similarly,birth date(option D) contributes to demographic data but is unrelated to the primary efficacy outcome.

Reference (CCDM-Verified Sources):

SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 – Critical Data Identification for Endpoints

ICH E9 – Statistical Principles for Clinical Trials, Section 2.2.3 – Time-to-Event Data Considerations

FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development